Market closedNon-fractional

Amgen/AMGN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Amgen

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Ticker

AMGN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Thousand Oaks, United States

Employees

26,700

Amgen Metrics

BasicAdvanced
$177B
Market cap
47.21
P/E ratio
$7.01
EPS
0.60
Beta
$8.64
Dividend rate
2.61%
Dividend yield
$177B
0.6
$8.64
1.422
0.836
1,195.958
1,274.791
122.96%
2.29%
4.88%
72.57%
47.212
5.999
35.34
-3.95
24.959
2.61%
12.76%
-52.39%
5.48%
-16.58%
9.62%

What the Analysts think about Amgen

Analyst Ratings

Majority rating from 31 analysts.
Buy

Amgen Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1.51% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$7.4B
-9.14%
Net income
-$113M
-114.73%
Profit margin
-1.51%
-116.15%

Amgen Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.32%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$5.00
$4.96
$4.71
$3.96
-
Expected
$4.49
$4.67
$4.61
$3.87
$4.97
Surprise
11.30%
6.16%
2.27%
2.32%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Amgen stock?

Amgen (AMGN) has a market cap of $177B as of July 14, 2024.

What is the P/E ratio for Amgen stock?

The price to earnings (P/E) ratio for Amgen (AMGN) stock is 47.21 as of July 14, 2024.

Does Amgen stock pay dividends?

Yes, the Amgen (AMGN) stock pays dividends to shareholders. As of July 14, 2024, the dividend rate is $8.64 and the yield is 2.61%. Amgen has a payout ratio of 122.96% on a trailing twelve-month basis.

When is the next Amgen dividend payment date?

The next Amgen (AMGN) dividend payment date is unconfirmed.

What is the beta indicator for Amgen?

Amgen (AMGN) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Amgen stock

Buy or sell Amgen stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing